Oct 3, 2026 · Science & Research Daily Digest
Science, space, biomedicine, and climate research highlights compiled for Oct 3, 2026, with summaries, links, and brief commentary.
I. Spaceflight and Deep Space
1. Prototype rover Charlie ends a two-week Mars-terrain trial in Tabernas (Spaceflight)
Summary:
El País reported on Oct 3 from the Tabernas desert in Almería, Spain, where ESA and Airbus are testing Charlie, a prototype of the ExoMars rover, on the last day of a campaign of about two weeks. Mission control is in Turin, about 1,645 kilometers away. Benoit Pouffary, head of ESA's ExPeRT team, said the local geology resembles the planned landing area. Jeremy Close of Airbus said Charlie and four other data-gathering rovers will not fly; they share the wheels, mast, and base of the flight rover Rosalind Franklin. That rover is scheduled to launch in 2028 and, after arrival in early 2030, drill about two meters down and analyze samples on board for signs of life. It is expected to receive a task list at the start of each sol, carry it out autonomously, and report back at the end of the sol. Journalists on site saw the six-wheel vehicle take more than an hour to travel one meter on uneven ground.
Links:
Commentary:
The trial checks wheel-terrain interaction and remote operations, not the lander; Schiaparelli hit Mars at about 540 kilometers per hour, and a slow desert traverse does not clear entry, descent, and landing for 2030.
II. Biomedicine
2. RAG-18 raises sarcolemmal utrophin in three boys with Duchenne muscular dystrophy (Neuromuscular)
Summary:
Ractigen Therapeutics gave a late-breaking oral presentation on Oct 3 at the 31st World Muscle Society Congress in Hiroshima on first-in-human Phase I data for the investigational small activating RNA RAG-18 (NCT07282652). The open-label dose-escalation trial enrolls ambulatory boys aged 4 to 15 with genetically confirmed Duchenne muscular dystrophy. Cohort 1 received 15 mg intravenously once a month (n=3), with data through day 169. Paired muscle biopsies on day 113 showed sarcolemmal utrophin signal density 3.5- to 5.3-fold above baseline in mature myofibers and 4.1- to 4.7-fold in regenerating myofibers. None of the three had a dose-limiting toxicity, a serious adverse event, or a Grade 3 or higher treatment-emergent adverse event. Function was uneven: six-minute walk distance rose 36.5 meters in a participant aged 6.8, changed by minus 1.0 meter at age 12.7, and fell 62.5 meters at age 7.3. North Star Ambulatory Assessment scores fell by 3 points in all three. Cohort 2, at 30 mg monthly, is fully enrolled. The FDA has granted orphan-drug and rare-pediatric-disease designations. The drug uses no viral vector and does not edit DNA.
Links:
Commentary:
Biopsies from three boys in an open-label cohort show the drug reached muscle and raised utrophin; the walk-test split means the tissue signal is not yet a clinical benefit.
3. NEJM publishes Phase 3 retatrutide obesity results, with 25% weight loss at the top dose over 80 weeks (Metabolism)
Summary:
ScienceAlert reported on Oct 3 on TRIUMPH-1, a randomized double-blind trial led by Ania Jastreboff and funded by Eli Lilly. It assigned 2,339 adults with obesity and without diabetes to weekly subcutaneous retatrutide at 4 mg, 9 mg, or 12 mg, or to placebo, for 80 weeks. The drug activates GLP-1, GIP, and glucagon receptors. The New England Journal of Medicine paper (DOI: 10.1056/NEJMoa2604169; Lilly's medical information page lists online-first publication on Sept 29, 2026) reports treatment-regimen weight changes of minus 17.6%, 23.7%, and 25.0%, versus minus 3.9% with placebo. In the intention-to-treat analysis, pain scores on a 0–10 scale among 574 participants with knee osteoarthritis fell by 4.1 points at 12 mg and 2.5 points on placebo. Among 243 participants with obstructive sleep apnea, breathing events fell by 32.1 per hour at 12 mg and 9.6 per hour on placebo. A prespecified extension enrolled 532 people; the 12 mg group reached 29.9% weight loss at 104 weeks on the treatment-regimen estimand. Participants who started on placebo switched to drug in the extension, so there is no two-year placebo comparison. ScienceAlert reported nausea in about 42% of the highest-dose group, discontinuation for adverse events in about 11% versus 4.6% on placebo, and serious adverse events in 10.5% versus 5.5%. The trial was not designed for cardiovascular safety and did not compare retatrutide with semaglutide or tirzepatide.
Links:
- NEJM — Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
- ScienceAlert — Ozempic rival delivers 25% weight loss at highest dose in phase 3 trial
Commentary:
The 25% figure is an 80-week treatment-regimen average against each person's starting weight, not an approved label; the near-30% figure at two years comes from the subset who entered the extension.
4. Phage-compatible peptide bicyclization yields a PD-1 ligand near 400 nM (Chemistry)
Summary:
Nature Communications on Oct 3 published an open-access paper by Guoqing Jin, Joshua Trae Hampton, Wenshe Ray Liu, and colleagues at Texas A&M University. They report PReP-Bicyc, an additive-free, phage-compatible, site-selective peptide bicyclization. The linker 4,6-dichloropyrimidine-2-carbonitrile first forms a thiazoline with an N-terminal cysteine; proximity then drives thiol arylation of two internal cysteines. Screening a modified CX4CX4C library against programmed cell death protein 1 produced sub-micromolar bicyclic ligands, the best with a dissociation constant of about 400 nM. The ligands selectively labeled PD-1-expressing cells and inhibited the PD-1/PD-L1 interaction. Support came from the U.S. National Institutes of Health, the Cancer Prevention and Research Institute of Texas, and the Welch Foundation.
Links:
Commentary:
A dissociation constant near 400 nM shows that a living phage display can yield a PD-1-binding bicycle; it is a discovery starting point, not a candidate with animal efficacy data.
III. Basic Research
5. Recordings from 624 superior-temporal neurons show semantic prediction reorganizing phonetic dynamics (Neuroscience)
Summary:
Nature Communications on Oct 3 published an open-access paper from the University of Geneva, Brown University, the University of California San Diego, Massachusetts General Hospital, and the University of Zurich and ETH Zurich, with Timothée Proix as corresponding author. The team analyzed 624 neurons in three participants implanted with microelectrode arrays in the anterior superior temporal gyrus during an auditory semantic categorization task and natural speech perception. Lexico-semantic and phonetic features occupied distinct low-dimensional neural subspaces. Comparing a bottom-up cumulative account with a top-down semantic account, phonetic activity aligned in time with word-level semantic representations, consistent with top-down prediction. The effect was consistent across the three participants at the spiking level and was not detected in adjacent electrocorticography.
Links:
Commentary:
The evidence comes from three people implanted for clinical care and shows that semantic expectation can reorganize phonetic population dynamics; it is not yet a speech model for the general population.
6. Single-atom counts in a strongly attractive Fermi gas still match random-matrix predictions (Quantum gases)
Summary:
Nature Communications on Oct 3 published an open-access paper by Tarik Yefsah and colleagues at Laboratoire Kastler Brossel (ENS-PSL, CNRS, Sorbonne Université, and Collège de France), with collaborators at Université Paris-Saclay, Toulouse, and theory groups in Paris. Random-matrix theory predicts counting statistics for non-interacting Fermi gases, but single-atom tests had been missing. The team counted atoms in situ in an ultracold Fermi gas of two spin states under strong attractive interactions. Despite that attraction, each spin component matched random-matrix predictions based on Fredholm determinants to high accuracy. The authors treat this as an experimental validation of the Fermi-sphere point process and argue that the description still applies to strongly interacting systems. Support came from the French National Research Agency, CNRS, and the Île-de-France region.
Links:
Commentary:
Strong attraction did not pull the single-component counts off the Fermi-sphere point process; the result tests counting statistics, not a new many-body Hamiltonian.
7. A branched spacer cation cuts moisture-driven degradation of a 2D perovskite powder by about sixfold (Materials)
Summary:
Nature Communications on Oct 3 published an open-access paper by Isaac Metcalf and Aditya D. Mohite at Rice University, Claudine Katan and Jacky Even at the University of Rennes, Esther H. R. Tsai at Brookhaven National Laboratory, and colleagues. After moisture intercalates, 2D halide perovskites degrade along a ternary phase diagram of spacer-cation iodide, lead iodide, and water. Spacer-cation chemistry decides whether low-energy non-perovskite phases can form. Stable 2D perovskites can typically coexist with water in thermodynamic equilibrium; unstable ones cannot, because hydrate phases block that equilibrium. Replacing linear butylammonium with branched isobutylammonium suppressed moisture-driven degradation of the corresponding 2D powders by a factor of about six. The authors also report that mixed-organic-cation non-perovskite phases can destabilize mixed 3D-2D films, and that suppressing those phases improves stability. Grazing-incidence wide-angle X-ray scattering used the National Synchrotron Light Source II at Brookhaven.
Links:
Commentary:
The sixfold figure compares powder degradation in humid air, not the lifetime of a packaged device; the design rule is to avoid low-energy hydrates, not a claim that perovskites are now waterproof.
IV. Climate and Energy
8. A NOAA model shows seasonal forecast skill for spring solar power in the southwestern United States (Energy meteorology)
Summary:
Communications Earth & Environment on Oct 3 published an open-access paper by Xiaosong Yang, Thomas L. Delworth, and colleagues at NOAA's Geophysical Fluid Dynamics Laboratory. Growing solar and wind capacity raises the need for usable seasonal forecasts. Using a seasonal forecast system, the authors report high prediction skill for springtime solar energy resources over the southwestern United States. Two sources dominate: a primary component tied to the main El Niño–Southern Oscillation state, and a secondary component tied to El Niño diversity and tropical Atlantic variability. Together they account for the spatial pattern of skill. State-level checks show robust solar skill in high-resource states. The same system captures compound wind-solar variability and historical co-fluctuations linked to seasonal energy droughts and surpluses.
Links:
Commentary:
The skill is for spring, the Southwest, and high-resource states; it is not yet a seasonal dispatch product for the national grid.
9. Perspective: decarbonization does not by itself retire oil-deliverability risk (Energy systems)
Summary:
Communications Sustainability on Oct 3 published an open-access perspective by Md Zishan Akhter and Philip Richard Hart at the Technology Innovation Institute in Abu Dhabi. They argue that replacing fossil generation with renewable electricity does not remove liquid fuels from essential services. Figures cited in the paper include 5,149 GW of global renewable capacity at the end of 2025, after a record 692 GW added in one year; about 24 million barrels per day of oil production still present in 2050 in the International Energy Agency's 1.5°C scenario; and, in the U.S. Energy Information Administration reference case, a 17.0% rise in liquid-fuel consumption from 2025 to 2050 (198.2 to 231.9 quadrillion Btu) while its share falls from 30.0% to 27.1%. Disruption of tanker traffic through the Strait of Hormuz in 2026 is used as an example; the strait carries more than one-quarter of seaborne oil trade. The authors recommend oil-deliverability stress tests in transition plans, with expiry conditions on emergency measures.
Links:
Commentary:
This is a comment that recasts existing outlooks as a security metric, not a new emissions inventory; 5,149 GW and 24 million barrels per day come from the cited agency publications.
Today's Summary
- Space: The ExoMars prototype Charlie finished a trial of about two weeks in Tabernas. The flight rover Rosalind Franklin is still planned for a 2028 launch, arrival in early 2030, and a drill to about two meters.
- Biomedicine: RAG-18 raised sarcolemmal utrophin 3.5- to 5.3-fold in three boys, with inconsistent walk-test results. Phase 3 retatrutide produced up to 25.0% weight loss on the treatment-regimen estimand at 80 weeks in 2,339 people. A bicyclic-peptide screen found a PD-1 ligand near 400 nM.
- Basic research: 624 superior-temporal neurons in three participants support top-down semantic prediction of phonetic activity. Single-spin counts in a strongly attractive Fermi gas still match random-matrix theory. Isobutylammonium cut moisture-driven degradation of a 2D perovskite powder by about sixfold.
- Climate and energy: A NOAA model shows interpretable seasonal skill for spring solar power in the southwestern United States. A perspective argues that liquid-fuel use still rises through 2050 in a reference case, so oil-deliverability risk does not vanish with renewable capacity.
Daily Framing:
Today was a small-sample and forecast-skill day: muscle biopsies and a triple-agonist weight-loss trial produced numbers that can be checked, while speech, Fermi-gas counts, and spring solar skill stayed at mechanism and seasonal scale.
This digest is compiled from real-time search results and is for reference only.